UNSPSC 51384801: Droxicam

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H11N3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F24ADO1E2D, chemically known as 5-methyl-3-(2-pyridyl)-2h,5h-1,3-oxazino(5,6-c)(1,2)benzothiazine-2,4(3h)-dione 6,6-dioxide but generally known as droxicam, which bears US NIH Compound Identifier 65679. European Medicines Agency schedules Droxicam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06419MIG.

UNSPSC 51384801 Droxicam, a Commodity code, is a pharmaceutical product designation with minimal recent state and local procurement activity directly targeting this specific drug. Instead, recent solicitations under this code frame pharmaceutical procurement much more broadly, emphasizing generic multi-source medications, naloxone, and direct-to-manufacturer prescription programs rather than droxicam specifically. State and local governments soliciting under this code span county health departments, state pharmacy benefit programs, and cooperative purchasing alliances that aggregate demand across multiple jurisdictions. The work actually being bought includes generic pharmaceutical supply agreements, over-the-counter product distribution, emergency response medications such as naloxone, and administrative infrastructure to manage direct contracting relationships between state agencies and pharmaceutical manufacturers outside traditional pharmacy benefit manager channels.

The geographic spread shows activity centered in Florida, Texas, and Minnesota, with cooperative purchasing extending to participating jurisdictions including Oregon. Representative recent opportunities include Seminole County, Florida's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (IFB60459723LAS, due July 26, 2023); the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs (HHS0017013, posted April 3, 2026) to inform future procurement strategy; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products (S1070000015802, due March 26, 2026), requiring vendors to meet cGMP and Drug Supply Chain Security Act certification, maintain relationships with at least two authorized wholesalers, and accept a 3 percent administrative fee on all contract purchases. The code shows limited droxicam-specific activity; vendors pursuing this space should expect demand to emerge through broader pharmaceutical supply agreements and cooperative purchasing vehicles rather than single-drug procurement.